

# Clinical Trial Protocol

## Iranian Registry of Clinical Trials

20 Jun 2026

### The effect of melatonin on the course of treatment and complications of sepsis in infants

#### Protocol summary

##### Study aim

The effect of melatonin on the course of treatment and complications of sepsis in infants

##### Design

This study will be a clinical trial, phase 3 and with no blinding. In this study, 50 infants under 28 days with sepsis based on Cochran's formula (25 infants in the intervention group and 25 infants in the control group) will be randomly entered into the study. Both groups will initially be matched for WBC, CRP, gestational age, patient gender, patient weight, and symptoms. In the neonatal intervention group, in addition to antibiotics, they will receive melatonin tablets at a dose of 3 mg every 12 hours for 3 days.

##### Settings and conduct

This study will be performed in the neonatal ward and neonatal intensive care ward. At the beginning of the diagnosis of sepsis and 72 hours after treatment, 5 cc of blood samples will be taken.

##### Participants/Inclusion and exclusion criteria

Inclusion criteria: 1- Parental consent 2- Infants under one month of age 3- Diagnosis of sepsis according to clinical and laboratory criteria 4- No patient being NPO 5- Absence of underlying diseases such as Down syndrome and ... 6- Infants with a gestational age of 37 weeks and above Exclusion criteria: 1- Dissatisfaction of parents 2- Death of the patient during melatonin administration 3- Existence of congenital anomalies 4- Existence of symptoms of Severe sepsis 5- Presence of congenital heart diseases 6- PO intolerance and frequent vomiting

##### Intervention groups

Melatonin tablets will be prescribed for infants under 28 days of age

##### Main outcome variables

Faster recovery from sepsis, prevention of complications of neonatal sepsis

#### General information

##### Reason for update

##### Acronym

##### IRCT registration information

IRCT registration number: **IRCT20210825052289N1**

Registration date: **2021-09-14, 1400/06/23**

Registration timing: **registered\_while\_recruiting**

Last update: **2021-09-14, 1400/06/23**

Update count: **0**

##### Registration date

2021-09-14, 1400/06/23

##### Registrant information

##### Name

Armin Ghahremanzadeh

##### Name of organization / entity

##### Country

Iran (Islamic Republic of)

##### Phone

+98 45 3325 2251

##### Email address

drarminghahreman@gmail.com

##### Recruitment status

##### Recruitment complete

##### Funding source

##### Expected recruitment start date

2021-09-11, 1400/06/20

##### Expected recruitment end date

2021-11-11, 1400/08/20

##### Actual recruitment start date

empty

##### Actual recruitment end date

empty

##### Trial completion date

empty

##### Scientific title

The effect of melatonin on the course of treatment and complications of sepsis in infants

**Public title**

Evaluation of the effect of melatonin in the treatment of sepsis

**Purpose**

Treatment

**Inclusion/Exclusion criteria****Inclusion criteria:**

Parental consent Infants under one month of age  
Diagnosis of sepsis according to clinical and laboratory criteria NPO patient(Non Pre Oral) absence of any underlying disease infants with gestational age above 37 weeks

**Exclusion criteria:**

Parental dissatisfaction Death of the patient during melatonin administration Existence of congenital anomalies Existence of severe sepsis Presence of congenital heart disease PO intolerance and frequent vomiting

**Age**

From **1 day** old to **28 days** old

**Gender**

Both

**Phase**

3

**Groups that have been masked**

*No information*

**Sample size**

Target sample size: **50**

More than 1 sample in each individual

Number of samples in each individual: **2**

At the beginning of the diagnosis of sepsis and 72 hours after treatment 5 cc blood sample will be taken.

**Randomization (investigator's opinion)**

Randomized

**Randomization description**

Patients will be enrolled randomly in to one of the groups based on inclusion criteria. Randomisation sequence will be processed by Microsoft Excel program via (RANDBETWEEN) command and numbers 0 and 1 will be allocated to each group to choose the group of the subject.

**Blinding (investigator's opinion)**

Not blinded

**Blinding description****Placebo**

Not used

**Assignment**

Other

**Other design features**

The aim of this study is , reduce hospitalization time and help improve neonatal sepsis treatment to prevent further complications.

**Secondary Ids**

empty

**Ethics committees****1****Ethics committee****Name of ethics committee**

Ethic committee of Ardabil University of Medical Sciences

**Street address**

Moallem Ave., Ardabil Town Bouali hospital

**City**

Ardabil

**Province**

Ardabil

**Postal code**

5613643197

**Approval date**

2021-08-09, 1400/05/18

**Ethics committee reference number**

IR.ARUMS.REC.1400.160

**Health conditions studied****1****Description of health condition studied**

sepsis in neonates

**ICD-10 code**

P36.9

**ICD-10 code description**

Bacterial sepsis of newborn, unspecified

**Primary outcomes****1****Description**

White blood cell

**Timepoint**

At the beginning of treatment and 3 days after treatment

**Method of measurement**

Acquiring venous blood sample

**2****Description**

C-Reactive Protein

**Timepoint**

At the beginning of treatment and 3 days after treatment

**Method of measurement**

Acquiring venous blood sample

**3****Description**

Interleukin-6

**Timepoint**

At the beginning of treatment and 3 days after treatment

**Method of measurement**

Acquiring venous blood sample

## Secondary outcomes

### 1

#### Description

Neonates general status

#### Timepoint

At the beginning of treatment and 3 days after treatment

#### Method of measurement

Based on Attending's evaluation in 3 categories: Well, Ill and Toxic

### 2

#### Description

Poorfeeding

#### Timepoint

At the beginning of treatment and 3 days after treatment

#### Method of measurement

Based on Attending's evaluation

### 3

#### Description

Outcome

#### Timepoint

Upon discharge

#### Method of measurement

Death or Living based on Attending's evaluation

### 4

#### Description

Length of hospital stay

#### Timepoint

Upon discharge

#### Method of measurement

Based on date's submitted to patient profile

## Intervention groups

### 1

#### Description

Intervention group: Patients of this group will receive Melatonin tablet from Normlife Company every 12 hours for 3 days.

#### Category

Treatment - Drugs

### 2

#### Description

Control group: Patients of this group will not receive Melatonin tablet.

#### Category

Treatment - Drugs

## Recruitment centers

### 1

#### Recruitment center

##### Name of recruitment center

Bouali hospital

##### Full name of responsible person

Armin Ghahremanzadeh

##### Street address

Moallem ave., Ardabil City

##### City

Ardabil

##### Province

Ardabil

##### Postal code

5613643197

##### Phone

+98 45 3325 2251

##### Email

Bouali@arums.ac.ir

## Sponsors / Funding sources

### 1

#### Sponsor

##### Name of organization / entity

Ardabil University of Medical Sciences

##### Full name of responsible person

Aziz Kamran

##### Street address

Moallem Ave., Ardabil Town

##### City

Ardabil

##### Province

Ardabil

##### Postal code

5613643197

##### Phone

+98 45 3325 2251

##### Email

Bouali@arums.ac.ir

#### Grant name

#### Grant code / Reference number

#### Is the source of funding the same sponsor organization/entity?

Yes

#### Title of funding source

Ardabil University of Medical Sciences

#### Proportion provided by this source

100

#### Public or private sector

Public

#### Domestic or foreign origin

Domestic

#### Category of foreign source of funding

*empty*

#### Country of origin

#### Type of organization providing the funding

Academic

## Person responsible for general inquiries

### Contact

**Name of organization / entity**

Ardabil University of Medical Sciences

**Full name of responsible person**

Armin Ghahremanzadeh

**Position**

Medical Resident

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Pediatrics

**Street address**

Bouali hospital, Moallem Ave., Ardabil Town

**City**

Ardabil

**Province**

Ardabil

**Postal code**

5613643197

**Phone**

+98 45 3325 2251

**Email**

Darminghahreman@gmail.com

## Person responsible for scientific inquiries

### Contact

**Name of organization / entity**

Ardabil University of Medical Sciences

**Full name of responsible person**

Armin Ghahremanzadeh

**Position**

Pediatrics Resident

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Pediatrics

**Street address**

Bouali hospital, Moallem Ave., Ardabil Town

**City**

Ardabil

**Province**

Ardabil

**Postal code**

5613643197

**Phone**

+98 45 3325 2251

**Email**

Draminghahreman@gmail.com

## Person responsible for updating data

### Contact

**Name of organization / entity**

Ardabil University of Medical Sciences

**Full name of responsible person**

Armin Ghahremanzadeh

**Position**

Pediatrics Resident

**Latest degree**

Medical doctor

**Other areas of specialty/work**

Pediatrics

**Street address**

Bouali hospital, Moallem Ave., Ardabil Town

**City**

Ardabil

**Province**

Ardabil

**Postal code**

5613643197

**Phone**

+98 45 3325 2251

**Email**

Darminghahreman@gmail.com

## Sharing plan

**Deidentified Individual Participant Data Set (IPD)**

Yes - There is a plan to make this available

**Study Protocol**

Yes - There is a plan to make this available

**Statistical Analysis Plan**

Yes - There is a plan to make this available

**Informed Consent Form**

Yes - There is a plan to make this available

**Clinical Study Report**

Yes - There is a plan to make this available

**Analytic Code**

Yes - There is a plan to make this available

**Data Dictionary**

Yes - There is a plan to make this available

**Title and more details about the data/document**

All information is shareable

**When the data will become available and for how long**

Start the access period after printing the results

**To whom data/document is available**

Available to university researchers.

**Under which criteria data/document could be used**

Can be used for similar research

**From where data/document is obtainable**

by Email Darminghahreman@gmail.com

**What processes are involved for a request to access data/document**

Have a letter of recommendation from the desired university.

**Comments**